Preoperative Levosimendan. A New Way for Organoprotection

Author(s): Guerrero Orriach Jose L, Ramirez Fernandez A., Iglesias P., Galan M., Melero JM., Florez A., Escalona J.J., Rodriguez M.J., Ramirez M., Rubio M., Cruz J.

Journal Name: Current Pharmaceutical Design

Volume 20 , Issue 34 , 2014

Become EABM
Become Reviewer


Preoperative use of levosimendan in cardiac surgery patients is one of the most attractive therapeutic alternatives in subjects with left or right ventricular dysfunction. Our review explores the pharmacological bases and clinical evidence for the use of levosimendan, with the intention of making a series of recommendations regarding its use in preoperative optimization prior to cardiac surgery. We carried out a survey of 102 Spanish anesthesiologists in order to shed light on the grey areas regarding the use of this drug prior to surgery.

Our findings suggest that levosimendan is recommended for patients with severe left or right ventricular dysfunction, moderate left ventricular dysfunction in which Intra-aortic Balloon Counterpulsation (IABC) is necessary and severe pulmonary hypertension. Administration of levosimendan prior to surgical cardiac intervention without an initial bolus reduces the likelihood of complications.

Keywords: Cardiac surgery, cardiac protection, levosimendan, preoperative treatment, preconditioning.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Page: [5476 - 5483]
Pages: 8
DOI: 10.2174/1381612820666140325121452
Price: $65

Article Metrics

PDF: 29